Inovio Pharmaceuticals (INO) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Inovio Pharmaceuticals (NASDAQ: INO):

  • 11/12/2026 – Inovio Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
  • 11/11/2026 – Inovio Pharmaceuticals had its “sell (e+)” rating reaffirmed by Weiss Ratings.
  • 11/11/2026 – Inovio Pharmaceuticals had its “overweight” rating reaffirmed by Piper Sandler. They now have a $6.00 price target on the stock, down from $8.00.
  • 11/6/2026 – Inovio Pharmaceuticals had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $8.00 price target on the stock, up from $3.00.
  • 11/2/2026 – Inovio Pharmaceuticals was given a new $5.00 price target by HC Wainwright. They now have a “buy” rating on the stock.
  • 11/2/2026 – Inovio Pharmaceuticals was upgraded by HC Wainwright from “neutral” to “buy”.
  • 10/12/2026 – Inovio Pharmaceuticals was downgraded by Zacks Research from “strong-buy” to “hold”.

Inovio Pharmaceuticals Stock Performance

Shares of INO stock traded up $0.23 on Tuesday, hitting $1.63. 15,602,997 shares of the stock traded hands, compared to its average volume of 27,654,768. Inovio Pharmaceuticals, Inc. has a twelve month low of $0.56 and a twelve month high of $2.72. The firm’s 50-day moving average price is $1.19 and its two-hundred day moving average price is $1.27. The stock has a market capitalization of $179.59 million, a PE ratio of -3.02 and a beta of 1.71.

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.29). The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $2.27 million. On average, equities research analysts anticipate that Inovio Pharmaceuticals, Inc. will post -0.97 EPS for the current fiscal year.

Inovio Pharmaceuticals, Inc. is a biotechnology company developing DNA medicines, including treatments intended to stimulate the body’s immune response to cancers and infectious diseases. Its research has focused on therapeutic and preventive applications, with candidates targeting conditions such as human papillomavirus (HPV)-related disease. The company’s technology uses synthetic DNA plasmids designed to prompt cells to produce targeted antigens. Inovio has also developed its CELLECTRA platform, which uses electroporation to help deliver DNA medicines into cells.

Read More

Receive News & Ratings for Inovio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.